Circulogene (Formerly Known As Circulogene Theranostics)

19 articles about Circulogene (Formerly Known As Circulogene Theranostics)

• CIRCULOGENE Announces Issuance of U.S. Patent for Method of Preparing Cell-Free Nucleic Acid Molecules by In Situ Amplification

  5/26/2021

  Issued patent recognizes CIRCULOGENE’s novel method of enriching cfDNA without DNA isolation, extraction or purification, enabling “in situ” genetic manipulation of biofluid samples

• CIRCULOGENE – Subcontractor to U.S. Department of Defense Research Award – to Develop Liquid Biopsy Markers for Traumatic Brain Injury

  6/17/2019

  $1.5 Million grant to The Geneva Foundation will use CIRCULOGENE’s liquid biopsy to quickly ID and accurately quantify organ-specific injury markers for improved treatment and survival in severely wounded military and civilian personnel

• CIRCULOGENE’s Precision Genomic Profiling Technology Featured in Three AACR 2019 Abstracts

  3/25/2019

  CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, will be presenting three abstracts at the 2019 American Association for Cancer Research (AACR) Annual Meeting, March 29 - April 3, 2019, at the Georgia World Congress Center in Atlanta.

• CIRCULOGENE Names Anthony L. Schmidt, M.D., as Medical Director

  2/19/2019

  CIRCULOGENE, advancing precision medicine through molecular genetics testing, has named Anthony L. Schmidt, M.D., F.A.C.P., as Medical Director.

• CIRCULOGENE Molecular Diagnostics Laboratory Receives College of American Pathologists (CAP) Accreditation

  2/13/2019

  CIRCULOGENE announced that its molecular diagnostics laboratory has received College of American Pathologists accreditation based on a recent on-site inspection as part of CAP’s Accreditation Programs.

• CIRCULOGENE to Launch Comprehensive, 20-Fusion NTRK Biomarker Testing in Early 2019

  12/20/2018

  Proprietary, cfRNA-enriched, real-time PCR testing rapidly identifies all patients with NTRK fusion-positive cancers potentially eligible for new TRK inhibitor targeted therapy

• CIRCULOGENE Expands Testing Menu with Somatic BRCA1/2 Blood Testing

  9/19/2018

  ​Enables paired somatic-germline testing, broadens targeted treatment population for breast, ovarian, pancreatic and prostate cancers.

• CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer Patients

  6/19/2018

  Independent UAB study demonstrates potential value of company’s molecular testing in noninvasive, serial tracking of genomic changes in treatment-resistant ovarian cancer

• CIRCULOGENE Announces Pilot Award Program for Cancer Research Sample Testing

  5/29/2018

  CIRCULOGENE is accepting grant applications for a cancer research sample testing pilot program.

• CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory

  1/4/2018

  Under terms of the agreement, CIRCULOGENE’s low-volume, high-yield, extraction-free and loss-free sample preparation coupled with next-generation sequencing technology is being licensed to CIRCULOGENE Saglik of Istanbul, Turkey.

• 

  CIRCULOGENE Names Dr. Glen J. Weiss as CMO

  11/29/2017

  Dr. Weiss will oversee and advance the laboratory’s research efforts and further educate oncologists about CIRCULOGENE’s next-generation sequencing (NGS) technology.

• CIRCULOGENE Introduces Single-Tube, Blood-Based Microsatellite Instability (MSI) Biomarker Testing for Multiple Cancers

  11/16/2017

  The advanced immunotherapy testing is immediately available to oncologists and pathologists, enabling them to identify patients eligible for treatment with Keytruda (pembrolizumab) across multiple cancer types, or Opdivo (nivolumab) for colorectal cancer.

• Circulogene Expands Liquid Biopsy Testing Capabilities, Adds Three cfRNA-based NSCLC Tests Supporting Personalized Treatment for Lung Cancer Patients

  5/23/2017

• New Research Involving Circulogene Theranostics’s Liquid Biopsy Further Validates Test’s Cancer Mutation Detection Capabilities

  6/22/2016

• Circulogene Theranostics Announces Four Abstracts Accepted For ASCO 2016 Conference

  5/20/2016

• AACR 2016 Research Shows Circulogene Theranostics Liquid Biopsy Excels At Real-Time Monitoring Of Cancer Mutations

  4/20/2016

• Circulogene Theranostics Accepts First International Orders For Cell-Free DNA Liquid Biopsy Testing

  3/2/2016

• Circulogene Theranostics Liquid Biopsy Research Accepted For Abstract Presentation At AACR Annual Meeting

  2/17/2016

• Circulogene Theranostics, UAB Comprehensive Cancer Center Join Forces, Announce Research Agreement

  2/11/2016